Table 1 Patient demographics and clinical characteristics at baseline
All patients (N = 56) | |
|---|---|
Age, years | 60.5 (38.0–70.0) |
Sex | |
Male | 37 (66.1%) |
Female | 19 (33.9%) |
ECOG performance status | |
0 | 25 (44.6%) |
1 | 31 (55.4%) |
Pathological type | |
Pancreatic ductal adenocarcinoma | 56 (100.0%) |
Pancreatic tumor location | |
Head | 17 (30.4%) |
Non-head | 39 (69.6%) |
Disease stage | |
Locally advanced disease | 1 (1.8%) |
Distant metastatic disease | 55 (98.2%) |
Number of organs with metastases | |
1 | 8 (14.3%) |
2 | 28 (50.0%) |
3 or more | 20 (35.7%) |
Metastatic sites (≥10%) | |
Liver | 40 (71.4%) |
Lymph nodes | 37 (66.1%) |
Peritoneum | 30 (53.6%) |
Lung | 12 (21.4%) |
Stage at initial diagnosis | |
I–III | 7 (12.5%) |
IV | 49 (87.5%) |
Stage before enrollment | |
III | 1 (1.8%) |
IV | 55 (98.2%) |
Prior therapy | |
Adjuvant chemotherapy | 5 (8.9%) |
Radical surgery | 7 (12.5%) |
PD-L1 CPS | |
<1 | 35 (62.5%) |
≥1 | 15 (26.8%) |
<5 | 42 (75.0%) |
≥5 | 8 (14.3%) |
<10 | 45 (80.4%) |
≥10 | 5 (8.9%) |
Not evaluable | 6 (10.7%) |
PD-L1 TPS | |
<1% | 44 (78.6%) |
1–49% | 6 (10.7%) |
Not evaluable | 6 (10.7%) |
CA19-9 level | |
≤UNL | 8 (14.3%) |
>UNL and ≤1000 U/ml | 22 (39.3%) |
>1000 U/ml | 26 (46.4%) |
